Extendicare Inc.
TSX:EXE.TOMedical - Care Facilities
+$0.86 today
- Market cap
- $2.74B
- Beta
- 1.16
- P/E (TTM)
- 26.4
- EPS (TTM)
- $1.28
- Dividend yield
- 1.51%
Volume 0.86M
Average 0.34M
EXE.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Extendicare Inc.TSX: EXE.TO
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month research & development was CA$0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 0 CAD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How EXE.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for EXE.TO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68M USD | -8.7% | -30.1% | 2.3% | |
| LTM Feb 2026 | $246.09K USD | -61.8% | -42.8% | 0.0% | |
| LTM Jun 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Sep 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding EXE.TO) | — | -61.8% | -36.4% | 0.0% | |
Competitors are the stored peer set for EXE.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.22B | 1.3B | 1.47B | 1.66B |
| Cost of Revenue | 1.05B | 1.14B | 1.14B | 1.3B | 1.46B |
| Gross Profit | 115.61M | 76.83M | 167.62M | 168M | 199.59M |
| Gross Margin | 9.9% | 6.3% | 12.8% | 11.5% | 12.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 69.79M | 51.08M | 55.84M | 1.2B | 1.36B |
| Operating Expenses | 52.43M | 50.78M | 55.84M | 56.94M | 61.22M |
| Depreciation & Amortization | 38.57M | 32.12M | 32.23M | 33.34M | 37.25M |
| EBITDA | 75M | 49.33M | 98.63M | 155.27M | 175.61M |
| EBITDA Margin | 6.4% | 4.0% | 7.6% | 10.6% | 10.6% |
| Operating Income | 49.71M | 20.99M | 62.96M | 111.21M | 138.37M |
| Operating Margin | 4.3% | 1.7% | 4.8% | 7.6% | 8.3% |
| Interest Income | 1.87M | 5.02M | 6.19M | 7.04M | 5.73M |
| Interest Expense | 22.45M | 21.7M | 21.6M | 21.1M | 19.23M |
| Other Income / Expenses | (35.72M) | (25.48M) | (18.16M) | (11.35M) | (8.26M) |
| Income Before Tax | 13.99M | (4.5M) | 44.8M | 99.86M | 130.1M |
| Pre-Tax Margin | 1.2% | -0.4% | 3.4% | 6.8% | 7.8% |
| Income Tax Expense | 6.48M | 15K | 10.82M | 24.65M | 33.45M |
| Net Income | 11.5M | 69.55M | 33.98M | 75.21M | 96.66M |
| Net Margin | 1.0% | 5.7% | 2.6% | 5.1% | 5.8% |
| EPS (Basic) | 0.13 | 0.85 | 0.40 | 0.97 | 1.13 |
| EPS (Diluted) | 0.13 | 0.85 | 0.40 | 0.86 | 1.11 |
| Weighted Avg Shares | 89.99M | 89.01M | 84.99M | 84.22M | 85.4M |
| Weighted Avg Shares (Diluted) | 100.9M | 89.01M | 84.99M | 95.36M | 86.84M |
Extendicare Inc.
TSX:EXE.TO
Intrinsic Alpha fair value
Locked
Current Price
$28.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.